[go: up one dir, main page]

WO1998018491A1 - Procedes et compositions pour la complementation alimentaire - Google Patents

Procedes et compositions pour la complementation alimentaire Download PDF

Info

Publication number
WO1998018491A1
WO1998018491A1 PCT/US1997/019564 US9719564W WO9818491A1 WO 1998018491 A1 WO1998018491 A1 WO 1998018491A1 US 9719564 W US9719564 W US 9719564W WO 9818491 A1 WO9818491 A1 WO 9818491A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
composition
factors
virus
raw
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/019564
Other languages
English (en)
Inventor
Carson B. BURGSTINER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Burgstiner Jacqueline Cook
Original Assignee
Burgstiner Jacqueline Cook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burgstiner Jacqueline Cook filed Critical Burgstiner Jacqueline Cook
Priority to CA002270223A priority Critical patent/CA2270223A1/fr
Publication of WO1998018491A1 publication Critical patent/WO1998018491A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • suppressor T-lymphocytes block the development of effector B and T lymphocytes.
  • Specific suppressor T-lymphocytes have now been demonstrated to play a large role in tolerance to many proteins, both in antibody and cell-mediated immune responses.
  • genetic unresponsiveness to some antigens is due to the greater stimulation of suppressor T-lymphocytes than of helper T-lymphocytes by these antigens.
  • the present invention provides a composition consisting essentially of thymus enzymatic polypeptide fractions, thymus extract, raw spleen, raw lymph, raw bone marrow, raw pituitary, vitamins A, D, C, E, B-l, B-2, B-6 and B-12, folic acid, niacinamide, biotin, pantothenic acid, calcium, iodine, magnesium, copper, zinc, selenium, potassium, manganese, chromium, boron, hesperidin, inositol, citrus bioflavinoid, choline, betaine HC1, octacosanol, para amino benzoic acid, rutin, trypsin, bromelain, papain, Echinacea angustifolia extract, Iris versicolor extract, Hydrastis canadensis extract, L-lysine, L-arginine, L-cysteine, L-hist
  • the present invention also provides methods for enhancing athletic performance in a subject, comprising administering the composition of the present invention to the subject.
  • the administration of the composition of the present invention to a subject results in an increase in total red blood cells in the subject, as demonstrated by increased hematocrit, thereby providing increased oxygen transport in the subject.
  • administration of the compositions of the present invention to a subject results in a more rapid flushing of lactic acid from the muscles, providing a shorter recovery time after athletic activity. The increase in red blood cells and shorter recovery time allow for enhancement of the subject's athletic performance.
  • compositions of the present invention provide components in combinations that are different from previously known compositions, in a delivery system for faster absorption by the body.
  • Vitamin B-l Thiamine Mononitrate 10 mg
  • Example 1 The composition in the dosage amounts of Example 1 is used to supplement the diet of a patient chronically infected with Hepatitis C virus. After continued dietary supplementation, the patient no longer tests positive for active Hepatitis C virus infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition comprenant des facteurs dérivés du thymus et des cofacteurs enzymatiques, lesdits facteurs dérivés du thymus pouvant être de l'extrait de thymus, des facteurs polypeptidiques enzymatiques thymiques, de la thymosine, de la thymopoïétine et le facteur humoral thymique et les cofacteurs enzymatiques pouvant être les vitamines A, C, D, E, B-1, B-2, B-6, B-12, des minéraux. Ladite composition peut également comprendre des acides aminés tels que l'arginine, la cystéine, l'histidine, l'ornithine, l'isoleucine, la leucine, la thréonine, la tyrosine, la valine, la phénylalanine et la méthionine. Elle peut également contenir des facteurs glandulaires tels que la rate brute, la lymphe brute, la moelle osseuse brute et l'hypophyse brute. L'invention porte aussi sur des méthodes d'augmentation des taux sériques de thymosine alpha 1 chez un sujet; d'activation du système immunitaire d'un sujet par l'augmentation des taux sériques de thymosine alpha 1 chez un sujet; de traitement d'une maladie auto-immune tels que le lupus érythémateux, la sclérose en plaques et la polyarthrite rhumatoïde chez un sujet; de traitement d'une infection virale induite par un virus tel qu'un virus de l'hépatite A, un virus de l'hépatite B, l'herpèsvirus, le virus de l'hépatite C et un virus de l'immunodéficience humain; et d'augmentation des performances athlétiques chez un sujet par l'augmentation de l'hématocrite et la réduction du temps de guérison, tous ces procédés consistant à administrer au sujet les compositions de l'invention.
PCT/US1997/019564 1996-10-28 1997-10-28 Procedes et compositions pour la complementation alimentaire Ceased WO1998018491A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002270223A CA2270223A1 (fr) 1996-10-28 1997-10-28 Procedes et compositions pour la complementation alimentaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2940396P 1996-10-28 1996-10-28
US60/029,403 1996-10-28

Publications (1)

Publication Number Publication Date
WO1998018491A1 true WO1998018491A1 (fr) 1998-05-07

Family

ID=21848824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019564 Ceased WO1998018491A1 (fr) 1996-10-28 1997-10-28 Procedes et compositions pour la complementation alimentaire

Country Status (2)

Country Link
CA (1) CA2270223A1 (fr)
WO (1) WO1998018491A1 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025764A3 (fr) * 1998-10-30 2000-07-13 Merck Patent Gmbh Compositions de traitement et de prevention de maladies cardio-vasculaires
US6180139B1 (en) * 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
EP1146878A4 (fr) * 1998-02-26 2002-12-04 Timothy Cochran Compositions biochimiques utilisees dans des traitements pour l'homme
EP1127572A3 (fr) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Utilisation de flavones dans le traitement de maladies induites par cyclooxygenase-2
JP2004002284A (ja) * 2001-11-30 2004-01-08 Ezaki Glico Co Ltd リウマチの症状改善用飲食品および医薬
KR100420560B1 (ko) * 2001-03-10 2004-03-02 임시웅 포도당과 아미노산의 상승작용에 의한 관절염 및관절손상의 예방 및 치료제
GB2396809A (en) * 2003-01-03 2004-07-07 Vitabiotics Ltd Composition for the treatment of HIV and AIDS
WO2005000331A3 (fr) * 2003-06-04 2005-05-26 Mucosal Therapeutics Inc Methodes et compositions permettant de traiter et de prevenir des troubles degeneratifs des articulations
WO2008050363A3 (fr) * 2006-10-27 2008-06-26 Sigma Tau Ind Farmaceuti Utilisation de thymosine alpha 1 pour la préparation d'un médicament destiné au traitement thérapeutique et préventif de maladies autoimmunes
US7452916B2 (en) 1993-06-11 2008-11-18 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US7618941B2 (en) 1999-04-23 2009-11-17 Rhode Island Hospital Treating degenerative joint disorders with tribonectins
US7910092B2 (en) 2006-03-10 2011-03-22 Tecnogen S.P.A. Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
US8557764B2 (en) 2007-01-26 2013-10-15 The Regents Of The University Of Colorado, A Body Corporate Methods of modulating immune function
US8957031B2 (en) 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US9359404B2 (en) 2011-12-01 2016-06-07 Scott & White Healthcare Methods and products for treating preeclampsia and modulating blood pressure
JP2016198052A (ja) * 2015-04-10 2016-12-01 味の素株式会社 アミノ酸含有組成物
US10716821B2 (en) 2013-07-22 2020-07-21 Université Du Québec A Chicoutimi Use of plant extracts against herpes simplex virus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698221A (en) * 1982-11-06 1987-10-06 Bayer Aktiengesellschaft Vaccines containing fat soluble vitamins, zinc compounds and selenium compounds
US4826680A (en) * 1985-10-23 1989-05-02 Dr. Kurt Mulli Nachf. Gmbh & Co. Kg Pharmaceutical composition containing thymus extract fractions
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698221A (en) * 1982-11-06 1987-10-06 Bayer Aktiengesellschaft Vaccines containing fat soluble vitamins, zinc compounds and selenium compounds
US4826680A (en) * 1985-10-23 1989-05-02 Dr. Kurt Mulli Nachf. Gmbh & Co. Kg Pharmaceutical composition containing thymus extract fractions
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452916B2 (en) 1993-06-11 2008-11-18 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
EP1146878A4 (fr) * 1998-02-26 2002-12-04 Timothy Cochran Compositions biochimiques utilisees dans des traitements pour l'homme
WO2000025764A3 (fr) * 1998-10-30 2000-07-13 Merck Patent Gmbh Compositions de traitement et de prevention de maladies cardio-vasculaires
US6180139B1 (en) * 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
US7018652B2 (en) 1998-12-04 2006-03-28 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
US7618941B2 (en) 1999-04-23 2009-11-17 Rhode Island Hospital Treating degenerative joint disorders with tribonectins
US8680057B2 (en) 1999-04-23 2014-03-25 Rhode Island Hospital Tribonectins
US8026346B2 (en) * 1999-04-23 2011-09-27 Rhode Island Hospital Tribonectins
EP1127572A3 (fr) * 2000-02-25 2003-05-02 Basf Aktiengesellschaft Utilisation de flavones dans le traitement de maladies induites par cyclooxygenase-2
KR100420560B1 (ko) * 2001-03-10 2004-03-02 임시웅 포도당과 아미노산의 상승작용에 의한 관절염 및관절손상의 예방 및 치료제
JP2004002284A (ja) * 2001-11-30 2004-01-08 Ezaki Glico Co Ltd リウマチの症状改善用飲食品および医薬
GB2396809A (en) * 2003-01-03 2004-07-07 Vitabiotics Ltd Composition for the treatment of HIV and AIDS
WO2005000331A3 (fr) * 2003-06-04 2005-05-26 Mucosal Therapeutics Inc Methodes et compositions permettant de traiter et de prevenir des troubles degeneratifs des articulations
US7910092B2 (en) 2006-03-10 2011-03-22 Tecnogen S.P.A. Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases
US8268304B2 (en) 2006-03-10 2012-09-18 Sigma-Tau Industrie Farmaceutiche Riunite Spa Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
JP2010507650A (ja) * 2006-10-27 2010-03-11 シグマ − タウ インデュストリエ ファーマシューティッツェ リウニーテ ソシエタ ペル アチオニ 自己免疫疾患の予防及び治療用の薬剤を調製するためのチモシンアルファ１の使用
WO2008050363A3 (fr) * 2006-10-27 2008-06-26 Sigma Tau Ind Farmaceuti Utilisation de thymosine alpha 1 pour la préparation d'un médicament destiné au traitement thérapeutique et préventif de maladies autoimmunes
US8557764B2 (en) 2007-01-26 2013-10-15 The Regents Of The University Of Colorado, A Body Corporate Methods of modulating immune function
US8957031B2 (en) 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US10420813B2 (en) 2007-10-23 2019-09-24 The Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US9359404B2 (en) 2011-12-01 2016-06-07 Scott & White Healthcare Methods and products for treating preeclampsia and modulating blood pressure
US10716821B2 (en) 2013-07-22 2020-07-21 Université Du Québec A Chicoutimi Use of plant extracts against herpes simplex virus
JP2016198052A (ja) * 2015-04-10 2016-12-01 味の素株式会社 アミノ酸含有組成物

Also Published As

Publication number Publication date
CA2270223A1 (fr) 1998-05-07

Similar Documents

Publication Publication Date Title
WO1998018491A1 (fr) Procedes et compositions pour la complementation alimentaire
US5824322A (en) Compositions and methods for growth promotion
Ridge et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone
Konishi et al. Antitumor effect induced by a hot water extract of Chlorella vulgaris (CE): resistance to Meth-A tumor growth mediated by CE-induced polymorphonuclear leukocytes
US6344220B1 (en) Product and method for treating joint disorders in vertebrates
CN1131712C (zh) 初乳肽及其用途
JPH10509955A (ja) 二次性免疫不全症の治療法
AU596986B2 (en) Biologically-active copolymers
AU2011282200B2 (en) Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment
US5234683A (en) Method of stimulating the immune system
JP2023025192A (ja) 筋肉の質及び／又は筋量のためのオレウロペイン又はクルクミンを使用する組成物及び方法
US5114708A (en) Method for stimulating growth in animals
CN107582566B (zh) 通过多胺化合物调控自身免疫性疾病的方法和组合物
JPS63301831A (ja) 相乗的免疫刺激組成物および方法
WO1995018625A1 (fr) Composition renfermant des extraits de tortues et notamment de tortues hargneuses, sa preparation et son utilisation
EP1718290B1 (fr) Composition a base de l-serine, de l-isoleucine, d'acide folique et d'oligo-elements, utilisee dans le traitement du psoriasis
WO2012038590A1 (fr) Substitut alimentaire amélioré pour le traitement ou la prévention du cancer
JP3602586B2 (ja) 餌料用組成物
WO2025020074A1 (fr) Peptides de collagène bioactifs et formulations de vitamine c
US20060193922A1 (en) Compositions and methods for the treatment of acne
JP3845447B2 (ja) タイプ▲ｉｉ▼コラーゲンによるリウマチ性関節炎治療方法
KR100518126B1 (ko) 렉틴조성물및이의용도
JPS6144822A (ja) コンドロイチン硫酸含有抗疲労剤
WO1999016456A1 (fr) Preparation ayant une activite biologique, complexe de preparations et procede de stimulation immunologique
US20180027853A1 (en) Embryonic egg extract composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2270223

Country of ref document: CA

Ref country code: CA

Ref document number: 2270223

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09297318

Country of ref document: US

122 Ep: pct application non-entry in european phase